Saturday 17 October 2026
Export CGEM’s income statement to Excel — free account
Cullinan Therapeutics, Inc.
CGEM Healthcare Biotechnology
In the quarter to June 2026, EPS grew 24.3% and free cash flow grew 33.7%, each against the same quarter a year earlier.
12.93
1.07
−7.64%
Follow CGEM
| Dec '17 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | 0.00 | — | — | — | — |
P/S ratio |
— | — | — | 0.00 | — | — | — | — |
Altman Z-Score |
— | — | — | 33.57 | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
— | — | — | 39.86 | — | — | — | — |
P/FCF ratio |
— | — | — | 0.00 | — | — | — | — |
P/Operating CF |
— | — | — | (43.81) | — | — | — | — |
P/B ratio |
— | — | — | 1.56 | — | — | — | — |
Price to Tangible BV |
— | — | — | 1.56 | — | — | — | — |
EV/Sales |
— | — | — | 0.00 | — | — | — | — |
EV/EBITDA |
— | — | — | 0.00 | — | — | — | — |
EV/Operating CF |
— | — | — | (8.62) | — | — | — | — |
EV/FCF |
— | — | — | (8.61) | — | — | — | — |
Quick Ratio |
— | 39.09 | 14.68 | 24.73 | 20.77 | 16.60 | 13.02 | 10.01 |
Current Ratio |
— | 39.67 | 14.82 | 25.25 | 21.09 | 17.07 | 13.53 | 10.25 |
Net Debt/EBITDA |
— | 4.44 | 3.49 | 4.28 | (3.23) | 2.45 | 2.03 | 1.57 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | 1.01 | 0.57 | 0.66 | (1.14) | 0.88 | 0.87 | 0.80 |
Capex/Depreciation |
— | (0.29) | (0.16) | 0.00 | (11.20) | (0.67) | 0.00 | (0.16) |
| — | 35.54% | (64.59%) | (20.96%) | 23.16% | (30.98%) | (32.06%) | (44.02%) | |
| — | (41.12%) | (32.87%) | (20.12%) | 22.28% | (29.30%) | (30.27%) | (41.09%) | |
ROIC |
— | 0.00% | 0.00% | (31.48%) | 133.46% | 0.00% | (64.32%) | (489.82%) |
Return on Tangible Assets |
— | (21.13%) | (26.15%) | (23.02%) | 24.54% | (33.81%) | (43.51%) | (62.92%) |
Average Days of Receivables |
— | — | — | 0.00 | — | — | — | — |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 304.87% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 153.86% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 128.68% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
— | — | — | 0.43 | — | — | — | — |
Graham Number |
— | — | — | 0.00 | — | — | — | — |
Earnings Yield |
— | — | — | (9.72%) | — | — | — | — |
Free Cash Flow Yield |
— | — | — | (6.54%) | — | — | — | — |
Revenue per Share |
— | 0.00 | 0.00 | 0.44 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
— | (3.27) | (1.50) | (1.01) | (2.80) | (3.23) | (2.70) | (2.98) |
Capex per Share |
— | 0.00 | 0.00 | 0.00 | (0.02) | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
— | (3.27) | (1.50) | (1.01) | (2.83) | (3.24) | (2.70) | (2.98) |
Cash per Share |
— | 15.42 | 10.57 | 6.74 | 10.35 | 11.24 | 7.42 | 6.40 |
Shareholders Equity per Share |
— | (6.24) | 10.07 | 9.87 | 11.85 | 10.92 | 10.98 | 6.92 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | (6.24) | 10.07 | 9.87 | 11.85 | 10.92 | 10.98 | 6.92 |
Free Cash Flow |
— | (20.92) | (29.78) | (43.43) | (127.71) | (134.48) | (145.30) | (175.80) |
Working Capital |
— | 97.57 | 197.96 | 284.82 | 451.97 | 452.05 | 384.02 | 349.02 |
Capital Expenditures |
— | (0.02) | (0.01) | — | (1.04) | (0.21) | — | (0.05) |
Net Current Asset Value |
— | (40.28) | 197.88 | 284.75 | 448.38 | 449.90 | 383.17 | 347.11 |
EV/EBIT |
— | — | — | 0.00 | — | — | — | — |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 |
Price to Operating Income |
— | — | — | 0.00 | — | — | — | — |
| Other line items | ||||||||
Depreciation/Fixed assets |
— | 0.38 | 0.48 | 0.69 | 0.08 | 0.31 | 0.45 | 0.74 |
Cash ROIC |
— | (35.62%) | (7.25%) | (6.07%) | (12.74%) | (14.60%) | (14.69%) | (22.35%) |
Accounts Receivable Turnover |
— | — | — | 0.00 | — | — | — | — |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Payables |
— | 5.31 | 5.31 | 6.42 | 2.91 | 2.58 | 2.09 | 1.26 |
Average Assets |
— | 50.23 | 157.58 | 325.95 | 499.15 | 522.65 | 553.00 | 535.10 |
Average Common Equity |
— | (58.12) | 80.20 | 312.84 | 480.20 | 494.46 | 522.11 | 499.53 |
Columns are period end dates